6-K ·Filed Jul 1, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago SEC0001575872-26-000476
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine administrative filing with no new financial data or material events. Monitor the AGM on July 23 for any strategic updates or guidance changes. The dividend record date of July 10 is the only near-term date to note.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
RDY ▼ -15.94% at T+20d
NEUTRAL call ✗ call lost -15.94% · α vs SPY -13.75% · entry $13.99 → $11.76
Next anchor: T+60d due 7d ago
Latest observation: T+57 -10.53% FF3 residual α
Entry anchored
Jun 30, 03:59 PM ET
via exchange tick
T+1d
+2.79%
call +2.79% · α +2.92%
$14.38
settled 3mo ago
T+5d
+4.57%
call +4.57% · α +4.31%
$14.63
settled 3mo ago
T+20d
-15.94%
call -15.94% · α -13.75%
$11.76
settled 2mo ago
T+60d
—
call — · α —
—
due 7d ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed a 6-K furnishing a letter to shareholders regarding the availability of the Integrated Annual Report for FY2025-26 and notice of the 42nd Annual General Meeting scheduled for July 23, 2026. The filing also confirms a final dividend of 8 per equity share with a record date of July 10, 2026. This is a routine administrative filing with no new material financial disclosures.

Key Facts

  • 42nd Annual General Meeting scheduled for July 23, 2026 at 11:00 a.m. IST via video conferencing
  • Final dividend of 8 per equity share declared for FY2025-26
  • Record date for dividend: July 10, 2026; payment on or before July 30, 2026
  • Integrated Annual Report for FY2025-26 made available to shareholders
  • No new material financial disclosures or operational updates in this filing

Financial Impact

Final dividend of 8 per equity share for FY2025-26 — routine capital return, no material financial impact beyond the dividend payment

dividend

Risk Factors

  • No material risks identified from this filing — it is purely administrative

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000476
Document: 0001575872-26-000476-index.html0001575872-26-000476
Document: 0001575872-26-000476.txt0001575872-26-000476
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access